Skip to content

Targeted Screening for Taenia Solium Tapeworms

Targeted Screening for Taenia Solium Tapeworms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01296958
Enrollment
1811
Registered
2011-02-16
Start date
2011-05-31
Completion date
2013-01-31
Last updated
2014-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Taenia Solium Taeniasis

Keywords

Taenia solium, cysticercosis, neurocysticercosis

Brief summary

The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.

Interventions

Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)

BEHAVIORALCommunity education campaign

Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.

Sponsors

National University of San Marcos, Peru
CollaboratorOTHER
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH
Oregon Health and Science University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All community members are eligible

Exclusion criteria

* Inability to provide informed consent

Design outcomes

Primary

MeasureTime frame
Porcine seroprevalenceEvery 4 months

Secondary

MeasureTime frame
Intestinal tapeworm prevalence16 months

Countries

Peru

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026